TITLE

FDA Clinical Hold on PLX Safety Study Trips Pluristem

AUTHOR(S)
Powers, Marie
PUB. DATE
June 2013
SOURCE
BioWorld Today;6/5/2013, Vol. 24 Issue 107, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the 14.4% decrease in stocks of Pluristem Therapeutics Inc. amid the decision of the U.S. Food and Drug Administration (FDA) to stop the U.S. Phase II study of its Placental expanded cell therapy. Zami Aberman, chairman and chief executive officer of the biotechnology company, explains the circumstances following the allergic reaction of a patient are still being investigated. The experimental drug is used for the treatment of peripheral artery disease.
ACCESSION #
88161857

 

Related Articles

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld Today;4/28/2010, Vol. 21 Issue 81, p1 

    This article reports on the plan of Pluristem Therapeutics Inc. to conduct Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. The Israeli company announced the plan after reporting positive results from two Phase I trials of the treatment,...

  • Will Cell-Based Therapy Shape Biopharma's Future?  // Contract Pharma;Jun2014, Vol. 16 Issue 5, p22 

    An interview with chief executive officer (CEO) Zami Aberman of biopharmaceutical company Pluristem is presented. Topics discussed by Aberman include the history of his stay at the company, the things needed to push stem cell injection technology to the next level, and the partners of the...

  • Other News To Note.  // BioWorld Today;5/14/2013, Vol. 24 Issue 92, p2 

    This section offers news briefs in the pharmaceutical industry as of May 2013. Biogen idec Inc. of Weston, Massachusetts, said the U.S. Food andl Drug Administration (FDA) accepted the firm's application for Eloctate in treating Hemophilia A. The Nasdaq OMX Group Inc. of New York reported...

  • Financings Roundup.  // BioWorld Today;9/24/2008, Vol. 19 Issue 186, p5 

    The article reports that Pluristem Therapeutics Inc. of New York City has raised additional fundings of $1 million in September 2008. These new fundings will be used to support the development of their preclinical allogenic, placenta-derived cell therapy products. As reported, Pluristem sold...

  • Pluristem's PLX-PAD Plans Boosted by $36M Offering. Boggs, Jennifer // BioWorld Today;1/28/2011, Vol. 22 Issue 19, p1 

    The article offers information on the public offering held by Pluristem Theraprutics Inc. to secure funding for its plans for a Phase II/III trial of placenta-derived cell therapy PLX-PAD for critical limb ischemia (CLI). The offering involved 11 million shares sold at 3.25 U.S. dollars each,...

  • Wound Care: Treatment Update.  // McKnight's Long-Term Care News;Apr2011, Vol. 32 Issue 4, p8 

    The article offers news briefs related to the medical care industry of the U.S. which include the partnership of Pluristem Therapeutics Inc. with NYU Medical Center, MIST Ultrasound Healing Therapy of Celleration Inc., and the approval of Derma Sciences Inc.'s MediHoney Gel Wound and Burn...

  • Pluristem files IND application to begin Phase I critical limb ischemia trial.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p10 

    The article reports on the investigational drug application filed by Pluristem Therapeutics to the U.S. Food and Drug Administration (FDA) in its aim to commence clinical trial with its placental-derived stromal cell product for the treatment of critical limb ischemia. The firm will begin its...

  • Financings Roundup.  // BioWorld Today;10/13/2010, Vol. 21 Issue 198, p6 

    The article reports that Pluristem Therapeutics Inc. have signed definitive agreements with selected institutional and private investors to sell restricted common stock and warrants to raise 5.25 million U.S. dollars.

  • PRODUCT BRIEFS.  // Medical Device Daily;5/14/2009, Vol. 13 Issue 92, p10 

    This section offers news briefs on the medical device industry. Cook Medical has launched its Spectrum Turbo-Ject PICC, an antibiotic-impregnated peripherally inserted central venous catheter (PICC) used for computed tomography (CT) scans. The U.S. Food & Drug Administration (FDA) has approved...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics